imugene thrilled as first patients dosed in vaxinia mast combination study
Published 1 year ago • 1.3K plays • Length 5:15Download video MP4
Download video MP3
Similar videos
-
4:00
first patient dosed in imugene's pd1-vaxx combination trial
-
2:30
imugene thrilled as first patient dosed in phase 1 oasis trial
-
4:15
imugene talks vaxinia mast trial and corporate ambition
-
6:40
imugene doses first patient in vaxinia phase 1 trial
-
3:51
imugene limited (asx:imu) three complete responses in azer-cel phase 1b trial
-
19:03
imugene steps up dosage at groundbreaking vaxinia cancer trial
-
9:07
juststocks speaks with imugene ceo and cf33 inventor on latest with company's clinical trials
-
5:20
imugene welcomes dosing of first patient in nextherizon phase 2 clinical trial
-
5:45
imugene begins dosing in cohort three of vaxinia monotherapy dose escalation trial
-
4:14
imugene doses first patient in phase 1 oncarlytics iv infusion combination trial
-
5:40
imugene secures ind approval for first-in-class oncarlytics trial
-
6:43
imugene's leslie chong welcomes first patient dosed in checkvacc trial
-
4:28
imugene with proactive at asx small and mid cap conference
-
22:33
the ovation-2 study and the novel immunotherapy imnn-001 for ovarian cancer
-
10:00
imugene begins vaxinia trial for bile tract cancer
-
9:34
imugene (asx: imu) – first patient dosed in checkvacc phase 1 trials
-
4:45
leslie chong's first interview following our news imugene secured two fda ind approvals
-
6:29
imugene finishes phase 1a monotherapy dose escalation of pd1 vaxx
-
1:34
dose-escalation and expansion study of ivosidenib in patients with idh1-mutant mds